Sit Investment Associates Inc. purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 19,550 shares of the company’s stock, valued at approximately $698,000.
Several other hedge funds have also recently added to or reduced their stakes in DBVT. Alliancebernstein L.P. boosted its stake in DBV Technologies by 21.1% in the first quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock valued at $35,098,000 after buying an additional 173,798 shares during the period. Jennison Associates LLC boosted its stake in DBV Technologies by 0.7% in the first quarter. Jennison Associates LLC now owns 537,726 shares of the company’s stock valued at $18,939,000 after buying an additional 3,577 shares during the period. Morgan Stanley boosted its stake in DBV Technologies by 89.9% in the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock valued at $8,805,000 after buying an additional 118,317 shares during the period. Exane Asset Management boosted its stake in DBV Technologies by 3.9% in the second quarter. Exane Asset Management now owns 143,000 shares of the company’s stock valued at $5,107,000 after buying an additional 5,394 shares during the period. Finally, Marshall Wace North America L.P. purchased a new stake in DBV Technologies during the first quarter valued at $3,566,000. Institutional investors own 48.64% of the company’s stock.
DBV Technologies S.A. (DBVT) traded up 0.05% during trading on Friday, hitting $43.57. The company had a trading volume of 191,229 shares. The stock’s market capitalization is $2.00 billion. The company’s 50 day moving average price is $41.83 and its 200-day moving average price is $36.39. DBV Technologies S.A. has a 1-year low of $31.87 and a 1-year high of $46.33.
Several analysts have recently weighed in on DBVT shares. BidaskClub cut DBV Technologies from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Zacks Investment Research upgraded DBV Technologies from a “sell” rating to a “hold” rating and set a $49.00 price target on the stock in a report on Tuesday, August 1st. Morgan Stanley restated an “overweight” rating on shares of DBV Technologies in a report on Monday, July 10th. Jefferies Group LLC restated a “buy” rating and set a $47.00 price target on shares of DBV Technologies in a report on Thursday, June 1st. Finally, ValuEngine cut DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, June 30th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. DBV Technologies has an average rating of “Buy” and an average target price of $48.83.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.